

Asia-Pacific Diabetes and Obesity Symposium 2025 Luncheon Seminar

Obesity as an Illness: From Social Stigma to Metabolic Signatures and the Promise of Tirzepatide

Date | November 15 (Sat.) 2025, 12:50~13:40

Venue | **Room 7 (706, 7F, Toshi Center Hotel Tokyo)**
2-4-1 Hirakawa-cho, Chiyoda-ku, Tokyo, 102-0093, Japan

Chair | **Dr. Tadahiro Kitamura**
Professor, Metabolic Signal, Institute for Molecular and
Cellular Regulation, Gunma University, Japan

Speaker | **Dr. Takumi Kitamoto**
Assistant Professor, Department of Diabetes, Metabolism
and Endocrinology, Chiba University Hospital, Japan

Co-sponsored by : Asia-Pacific Diabetes and Obesity Symposium 2025
Mitsubishi Tanabe Pharma Corporation / Eli Lilly Japan K.K.

Please refrain from posting information about this seminar on social media etc.

Zepbound is a product subject to the Optimal Clinical Use Guidelines.

The approved indication of Zepbound in Japan is as follows:

“Obesity disease — only for patients who have hypertension, dyslipidemia, or type 2 diabetes, and who have not achieved sufficient effect through diet and exercise therapy, and who meet one of the following conditions:

- BMI ≥ 27 kg/m² with two or more obesity-related comorbidities, or
- BMI ≥ 35 kg/m²